Auriga Downgrades McKesson (MCK) to Hold; Drilling Down...Strong Q4 From Stock Buybacks
Tweet Send to a FriendGet Alerts MCK Hot Sheet
Price: $118.02 --0%
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Trade MCK Now!
Auriga downgraded McKesson (NYSE: MCK) from Buy to Hold with a price target raised to $98.00.
Analyst, Gene Mannheimer, said, "We are downgrading shares of McKesson following strong Q4 results and an upbeat FY13 outlook. Drilling down, we note an aggressive share repurchase program driving $0.22 of EPS. We are raising our FY13 estimates while introducing FY14 estimates. The estimate raise drives our price target to $98, from $95, though not enough to justify a BUY at current valuation. Management indicated that FY13 will be a record year for oral generic launches, benefitting profit in Distribution Solutions albeit no to modestly negative growth in direct revenues. We have some skepticism over the longer term profitability of certain generics beyond their exclusivity period (e.g. atorvastatin), and the back-end loaded nature of Technology Solutions, as we expect customer attrition as some clients move in the direction of Epic and Cerner (Nasdaq: CERN)(BUY)."
For an analyst ratings summary and ratings history on McKesson click here. For more ratings news on McKesson click here.
Shares of McKesson closed at $91.41 yesterday, with a 52 week range of $67.59-$92.69.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Gene Mannheimer, said, "We are downgrading shares of McKesson following strong Q4 results and an upbeat FY13 outlook. Drilling down, we note an aggressive share repurchase program driving $0.22 of EPS. We are raising our FY13 estimates while introducing FY14 estimates. The estimate raise drives our price target to $98, from $95, though not enough to justify a BUY at current valuation. Management indicated that FY13 will be a record year for oral generic launches, benefitting profit in Distribution Solutions albeit no to modestly negative growth in direct revenues. We have some skepticism over the longer term profitability of certain generics beyond their exclusivity period (e.g. atorvastatin), and the back-end loaded nature of Technology Solutions, as we expect customer attrition as some clients move in the direction of Epic and Cerner (Nasdaq: CERN)(BUY)."
For an analyst ratings summary and ratings history on McKesson click here. For more ratings news on McKesson click here.
Shares of McKesson closed at $91.41 yesterday, with a 52 week range of $67.59-$92.69.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- UPDATE: Sidoti Downgrades Texas Industries (TXI) to Neutral
- JMP Securities Downgrades MicroStrategy (MSTR) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Stock Buyback, Auriga
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
